ABSTRACT Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key metabolic enzymes,
converting isocitrate to α-ketoglutarate (αKG). IDH1 and IDH2 mutations have been …

Alterations to genes involved in cellular metabolism and epigenetic regulation are
implicated in the pathogenesis of myeloid malignancies. Recurring mutations in isocitrate …

The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for
the evaluation, diagnosis, and management of patients with MDS based on a review of …

Mutations in metabolic enzymes, including isocitrate dehydrogenase 1 (IDH1) and IDH2, in
cancer strongly implicate altered metabolism in tumorigenesis. IDH1 and IDH2 catalyze the …

Current standard-of-care (SOC) therapy for breast cancer includes targeted therapies such
as endocrine therapy for estrogen receptor-alpha (ERα) positive; anti-HER2 monoclonal …

Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key metabolic enzymes that convert
isocitrate to α-ketoglutarate. IDH1/2 mutations define distinct subsets of cancers, including …

Myelodysplastic syndromes are clonal marrow stem-cell disorders, characterised by
ineffective haemopoiesis leading to blood cytopenias, and by progression to acute myeloid …

The development of effective treatment strategies for most forms of acute myeloid leukemia
(AML) has languished for the past several decades. There are a number of reasons for this …

Purpose To study the incidence and prognostic impact of mutations in DNA
methyltransferase 3A (DNMT3A) in patients with acute myeloid leukemia. Patients and …

Ivosidenib is a first-in-class mutant isocitrate dehydrogenase 1 (m IDH1) inhibitor with
efficacy and tolerability in patients with advanced m IDH1 hematologic malignancies …